CD83 and metastatic malignant neoplasm in the lymph nodes: In agreement with this, patients with a significantly higher number of mature CD83+ cDCs at the invasive margin had a lower incidence of lymph-node metastasis and overall better outcomes in comparison to patients with reduced levels of CD83+ cDCs [89].